RETURN TO STORE HOME
CE Article: Infantile Hemangioma: A Review of Current Pharmacotherapy Treatment and Practice Pearls

Date: 12/16/2020

Infantile Hemangioma: A Review of Current Pharmacotherapy Treatment and Practice Pearls
Tiemann L, Hein S. Infantile Hemangioma: A Review of Current Pharmacotherapy Treatment and Practice Pearls. J Pediatr Pharmacol Ther 2020;25(7):586–599 DOI: 10.5863/1551-6776-25.7.586

 

Learning Objectives for Pharmacists

At the end of this session, participants will be able to:

  1. Define the pathogenesis of lifecycle of infantile hemangiomas
  2. Recognize infantile hemangioma lesions that are at high risk of complications
  3. Recognize complications of infantile hemangiomas and available treatment options
  4. Understand first- and second-line treatment options for infantile hemangiomas, including dosing regimens, monitoring, adverse effects, and treatment response
     

Course Details and Instructions

Accreditation

PPA has accredited this knowledge-based article for 1.0 contact hours (0.10 CEUs) of continuing education credit for pharmacists. UAN #:0180-0000-20-013-H01-P. The Pediatric Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to receive credit, participants must register for the program, read the article, pass a post-test, and fill out a post-program survey. Program expires in December 2023

Webinar and online programs are 100% supported through program registration fees and PPA membership dues, and is not supported by Industry.

 

BCPPS Recertification Credit is also available for this activity. Participants will be required to complete an evaluation and pass an exam in order to receive their certificate. Once the exam is passed, participants will receive 1 hour BCPPS credit. Valid through December 20, 2021.